Last reviewed · How we verify
Matching Placebo subcutaneous injection
A placebo injection that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.
At a glance
| Generic name | Matching Placebo subcutaneous injection |
|---|---|
| Also known as | Placebo, Study Drug |
| Sponsor | Minneapolis Heart Institute Foundation |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Matching placebo is an inert subcutaneous formulation designed to mimic the appearance, administration route, and schedule of an active investigational drug in blinded clinical trials. It allows researchers to isolate the true therapeutic effect of the active agent by controlling for placebo response and other non-specific effects of treatment and observation.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis (PHASE2)
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) (PHASE3)
- A Study of Barzolvolimab in Patients With Atopic Dermatitis (PHASE2)
- A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (PHASE2)
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) (PHASE3)
- HEALEY ALS Platform Trial - Master Protocol (PHASE2, PHASE3)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: